Among the new coagulation STOPP criteria are vitamin K antagonist as first line anticoagulant for atrial fibrillation (C11) and P-glycoprotein (P-gp) drug efflux pump inhibitors making a direct oral anticoagulant (DOAC) potentially inappropriate (C14). Here, PGP is linked to atrial fibrillation.